Asuragen, Inc.

134 articles about Asuragen, Inc.

• Asuragen, Inc.'s QuantideX qPCR BCR-ABL IS Kit Receives FDA Premarket Clearance For Monitoring Minimal Residual Disease In Chronic Myeloid Leukemia

  7/25/2016

• Asuragen, Inc. Launches The Amplidex PCR/CE C9orf72 Kit For High-Resolution Genotyping Of GC-Rich Repeat Expansions Relevant To Amyotrophic Lateral Sclerosis And Frontotemporal Dementia

  7/6/2016

• Asuragen, Inc. To Present Expansion Of Next-Generation Sequencing Portfolio At AACR Annual Meeting

  4/18/2016

• Asuragen, Inc. Names Colin Hill Senior Vice President Of Commercial Operations

  2/10/2016

• Asuragen, Inc. Launches Amplidex PCR/CE FMR1 Reporter*, A Fully Automated Software Solution For Accurate Sizing Of The FMR1 CGG Repeat Region

  11/5/2015

• Asuragen, Inc. To Present At Upcoming 2015 Association For Molecular Pathology Annual Meeting In Austin, TX

  11/3/2015

• Asuragen, Inc. To Collaborate With Illumina On Companion Diagnostics Development

  9/9/2015

• Asuragen, Inc. Launches The Quantidex Pan Cancer Kit, A Workflow Solution For Targeted Next-Generation Sequencing

  7/8/2015

• Asuragen, Inc. Announces Launch Of Highly Sensitive CE-IVD BCR-ABL Assay At The European Hematology Association Annual Congress

  6/11/2015

• Asuragen, Inc. To Present Innovations In Fragile X Testing At Upcoming American College Of Medical Genetics And Genomics (ACMG) Annual Clinical Genetics Meeting

  3/24/2015

• Asuragen, Inc. To Join Leading UK Cancer Research Consortium To Develop Mirna Based Sequencing Tests For Early Detection And Screening Of Cancer

  1/12/2015

• Asuragen, Inc. To Present At Upcoming Association For Molecular Pathology Annual Meeting In National Harbor, MD

  11/11/2014

• Asuragen, Inc. Launches The Quantidex™ DNA Assay To Improve The Accuracy Of Next-Generation Sequencing

  11/11/2014

• Asuragen, Inc.’s Xpansion Interpreter® Test Study Of 1,040 Transmissions Of Fragile X Alleles Reveals Personalized Risks For Expansion From Parent To Child

  9/17/2014

• Company Profile For Asuragen, Inc.

  8/15/2014

• Asuragen, Inc. Names Matthew McManus, M.D., Ph.D., President And CEO

  8/5/2014

• Asuragen, Inc. Receives New York State License For Molecular Genetic And Oncology Clinical Laboratory Testing

  7/10/2014

• Asuragen, Inc. Receives Notice of Patent Allowance for Broad Diagnostic Application of miR-21 in Cancer

  10/8/2013

• Exiqon A/S and Asuragen, Inc. Sign Agreement for Real-Time PCR Services

  6/10/2013

• Asuragen, Inc. Launches SuraSeq™ Next Generation Sequencing Panel in Its CAP Accredited CLIA Laboratory

  5/30/2013